Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 286 results for "Zohydro"

FDA Approves New Formulation of Zohydro ER
HCPLive

FDA approves tamper-resistant reformulation of Zohydro in cont...

The FDA approved a reformulated version of Zogenix's ($ZGNX) painkilling Zohydro ER designed to be abuse resistant, marking another step in the battle against opioid abuse and another chapter in a long-running battle over the controversial and ... Fierce Drug Delivery, 3 weeks ago
FDA Okays Abuse-Deterrent Zohydro ER Dermatology Online Journal, 3 weeks ago
[x]  

3 images for "Zohydro"

Business Insurance, 3 weeks ago
HCPLive, 3 weeks ago
Seeking Alpha, 1 month ago

Zogenix gets approval for new version of painkiller

Zogenix Inc. has received U.S. approval for a new formulation of its much-debated painkiller Zohydro that is intended to be harder to abuse, though the company is still working on studies needed to
 Yahoo! UK and Ireland3 weeks ago
[x]  

FDA OK's new Zohydro formulation; abuse-deterrent claims pending

:50:21 GMT 2015 Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK ...
 Scrip3 weeks ago

FDA accepts for review Teva's NDA for pain management tablets

The US Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) for Teva Pharmaceutical's hydrocodone bitartrate extended-release (ER) tablets formulated with its abuse deterrence technology (CEP-33237) for pain ...
 Pharmaceutical Business Review2 days ago Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology  World Energy Source3 days ago US FDA accepts for review Teva's NDA for hydrocodone bitartrate ER tablets with proprietary abuse deterrence technology  PharmaBiz1 day ago Teva Pharmaceutical Industries Announces FDA Acceptance For Review Of NDA For Its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets With Proprietary Abuse Deterrence Technology  BioSpace2 days ago
[x]  

FDA Assesses Teva's Abuse-Deterrent Hydrocodone

Teva Pharmaceutical Industries recently announced that the FDA has accepted for review a New Drug Application (NDA) for its investigational formulation of extended-release hydrocodone bitartrate with abuse-deterrent properties. The NDA seeks the ...
 Pharmacy Times2 days ago FDA Accepts Teva's NDA for Abuse-Deterrent Opioid  PharmaceuticalProcessing2 days ago
Seeking Alpha

2 Attractive Small-Cap Biotech Stocks On The Verge Of Breakouts

The small cap biotech & biopharma spaces are inherently volatile but have delivered huge winners to my portfolio over the past six months. I believe in building a well-diversified portfolio by taking small stakes across a myriad of promising ...
 Seeking Alpha3 days ago

FDA agrees to review Pfizer's abuse-deterring opioid candidate

Pharma bigwig Pfizer ($PFE) announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02. The capsules' pellets contain ‚Äčthe opioid receptor antagonist naltrexone ...
 Fierce Drug Delivery1 week ago UPDATED: FDA agrees to review Pfizer's abuse-deterring opioid candidate  Fierce Drug Delivery1 week ago

5 Reasons I Am Not Adding Biogen Idec To My Healthcare Portfolio

Feb. 18, 2015 2:09 PM ET | About: Biogen Idec Inc. (BIIB), Includes: AMGN, BAX, JNJ, LLY, MS, PFE by: Investing Healthcare Summary BIIB revenue growth is expected to decelerate this year versus years past. Catalysts in treating pain and ...
 Seeking Alpha1 week ago

FDA to Review 2 Abuse-Deterrent Opioids

The FDA recently accepted for review New Drug Applications (NDAs) for Collegium Pharmaceuticals extended-release oxycodone formulation (Xtampza ER) and Pfizer's extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair ...
 Pharmacy Times1 week ago Abuse-Deterrent Morphine Under FDA Review  Pharmacy Times2 weeks ago

Lynch, Rogers Launch Congressional Caucus on Prescription Drug Abuse

WASHINGTON, D.C. - Prescription drug abuse continues to be a serious issue for families and communities across our nation. As part of their efforts to fight this alarming epidemic, Congressman Stephen F. Lynch (MA-08) and Congressman Harold "Hal" ...
 Noodls2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Zohydro
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less